Neu Differentiation Factor (Heregulin) Induces Expression of Intercellular Adhesion Molecule 1: Implications for Mammary Tumors

作者: Sarah S. Bacus , Yosef Yarden , Ilana Stancovski , Carolyn R. Zelnick , Michael Sela

DOI:

关键词: Cellular differentiationCancer researchProtein kinase CNeuregulinCalphostin CCell adhesion moleculeTyrosine phosphorylationBiologyAdenocarcinomaMammary tumorInternal medicineEndocrinology

摘要: Neu differentiation factor (NDF, also called heregulin) is a 44-kilodalton glycoprotein that stimulates tyrosine phosphorylation of the Neu/HER-2 receptor and induces phenotypic certain mammary cancer cell lines to growth-arrested milk-producing cells. To determine which molecules participate in concomitant morphological alterations, we analyzed expression several cytoskeletal surface found NDF elevated intercellular adhesion molecule 1 (ICAM-1) cultured AU-565 human adenocarcinoma The levels both protein mRNA ICAM-1 were after 3-5 days treatment with NDF. Elevated was induced by gamma-interferon tumor-promoting phorbol ester (PMA), albeit different kinetics. Down-regulation kinase C or its inhibition calphostin partially inhibited effect NDF, implying induction may be mediated C. transcripts detectable 3 9 tumors, suggesting vitro relevant breast cancer. By selecting Neu-positive tumors (n = 39), significant correlation (P < 0.001) between histological features invasive ductal carcinoma prominent situ component. When cells these grew clusters formed domelike structures reminiscent comedo-type situ. In addition, majority patients coexpressed had no lymph node involvement, unlike most but ICAM-1-negative metastasized lymphatic system. Taken together, our observations suggest affect morphology, state, metastasis Neu-expressing tumor

参考文章(48)
Ilana Stancovski, Michael Sela, Yosef Yarden, Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase Cancer treatment and research. ,vol. 71, pp. 161- 191 ,(1994) , 10.1007/978-1-4615-2592-9_9
T Lam, K L Trimpe, P J Marks, W P Carney, S J McKenzie, J Morgan, D L Panicali, Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene. ,vol. 4, pp. 543- 548 ,(1989)
E. Peles, R.B. Levy, E. Or, A. Ullrich, Y. Yarden, Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. The EMBO Journal. ,vol. 10, pp. 2077- 2086 ,(1991) , 10.1002/J.1460-2075.1991.TB07739.X
Y. Suda, S. Aizawa, Y. Furuta, T. Yagi, Y. Ikawa, K. Saitoh, Y. Yamada, K. Toyoshima, T. Yamamoto, Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659----Glu659). The EMBO Journal. ,vol. 9, pp. 181- 190 ,(1990) , 10.1002/J.1460-2075.1990.TB08094.X
R Rothlein, R W Barton, C Kennedy, J Ksiazek, The effect of anti-intercellular adhesion molecule-1 on phorbol-ester-induced rabbit lung inflammation. Journal of Immunology. ,vol. 143, pp. 1278- 1282 ,(1989)
Robert Rothlein, Jordan S. Pober, Timothy A. Springer, Lynne A. Lapierre, Michael A. Gimbrone, Walter Fiers, Donna L. Mendrick, Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. Journal of Immunology. ,vol. 137, pp. 1893- 1896 ,(1986)
Joseph F. Gera, Alan Lichtenstein, Agnes M. Gardner, Catherine Fady, Interferon-induced Increase in Sensitivity of Ovarian Cancer Targets to Lysis by Lymphokine-activated Killer Cells: Selective Effects on HER2/neu-overexpressing Cells Cancer Research. ,vol. 52, pp. 764- 769 ,(1992)
Pier Paolo Di Fiore, C. Richter King, Philip G. Kasprzyk, Sun Uk Song, Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies Cancer Research. ,vol. 52, pp. 2771- 2776 ,(1992)
D C Allred, G M Clark, A K Tandon, R Molina, D C Tormey, C K Osborne, K W Gilchrist, E G Mansour, M Abeloff, L Eudey, HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. Journal of Clinical Oncology. ,vol. 10, pp. 599- 605 ,(1992) , 10.1200/JCO.1992.10.4.599